ImmunoGen Message Board - Msg: 32399210

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 3:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Gary Mohilner	11/1/2019 5:35:59 PM
	Read Replies (1) of 5665

The nice move IMGN made today was based on a positive quarterly presentation. In the presentation they announced that at ASH they'll have 4 presentations on IMGN632 and while nothing specific was noted, the data being presented is for double or more the previously reported on patients in the trial, it was pretty clear that this will be quite positive. I believe IMGN could be up substantially through the end of the year and close the year much higher to the high for the year, rather than the low where it's been since the Phase 3 results for IMGN853 were announced. I also should note that the new Phase 3 should begin before year's end, and that if they had recruited patients that met the higher, rather than lower, criteria for the trial, they could have met the approval criteria for at least the highest platinum resistant group. The new trial will assure that the trial is properly balanced. This is my interpretation of what was said, they didn't clearly state this is the case. Anyone interested should go to the website and listen to the quarterly presentation. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next